Univariate and multivariate analysis of prognostic factors in 100 patients with transformed MF
| Characteristic . | No. . | Median survival, mo . | DSS, % . | Univariate analysis DSS . | Multivariate analysis DSS . | OS, % . | Univariate analysis OS . | Multivariate analysis OS . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 y . | 5 y . | 10 y . | HR (95% CI) . | P . | HR (95% CI) . | P . | 2 y . | 5 y . | 10 y . | HR (95% CI) . | P . | HR (95% CI) . | P . | |||
| Sex | .418 | .980 | ||||||||||||||
| Male | 64 | 25 (1-235) | 65 | 38 | 38 | 1 | 59 | 31 | 21 | 1 | ||||||
| Female | 36 | 20 (2-160) | 56 | 38 | 32 | 1.3 (0.7-2.2) | 54 | 37 | 30 | 1 (0.6-1.6) | ||||||
| Age | .395 | .043 | .071 | |||||||||||||
| < 60 y | 34 | 42.5 (3-215) | 70 | 40 | 40 | 1 | 70 | 40 | 36 | 1 | 1 | |||||
| ≥ 60 y | 66 | 19 (1-235) | 57 | 38 | 33 | 1.3 (0.7-2.2) | 47 | 29 | 16 | 1.7 (1.0-2.9) | 1.9 (0.9-4.0) | |||||
| Time interval between MF and LCT | .089 | .322 | .246 | .475 | ||||||||||||
| ≤ 24 mo | 63 | 30 (2-215) | 71 | 44 | 39 | 1 | 1 | 66 | 36 | 25 | 1 | 1 | ||||
| > 24 mo | 37 | 17 (1-235) | 46 | 29 | 29 | 1.6 (0.9-2.7) | 1.4 (0.7-2.5) | 42 | 26 | 23 | 1.3 (0.8-2.2) | 1.3 (0.7-2.3) | ||||
| Clinical stage at LCT | .021 | .046 | .224 | .002 | ||||||||||||
| Skin disease (stage IB + stage IIB) | 75 | 26 (1-235) | 69 | 44 | 44 | 1 | 1 | 59 | 36 | 26 | 1 | 1 | ||||
| Extracutaneous disease (stage IV) | 25 | 20 (3-215) | 42 | 23 | 17 | 1.9 (1.1-3.3) | 1.9 (1.0-3.7) | 42 | 23 | 17 | 1.4 (0.8-2.3) | 3.2 (1.5-6.6) | ||||
| CD30 expression | .003 | .039 | .007 | .068 | ||||||||||||
| Positive | 47 | 38 (1-215) | 78 | 55 | 50 | 1 | 1 | 70 | 49 | 33 | 1 | 1 | ||||
| Negative | 53 | 20 (2-235) | 48 | 24 | 24 | 2.3 (1.3-4.1) | 2.0 (1.0-3.7) | 46 | 19 | 16 | 2.0 (1.2-3.2) | 1.8 (1.0-3.3) | ||||
| Folliculotropic MF | .060 | .048 | .318 | |||||||||||||
| Absent | 69 | 25 (1-235) | 67 | 45 | 42 | 1 | 1 | 57 | 37 | 25 | 1 | |||||
| Present | 31 | 22 (2-134) | 52 | 25 | 25 | 1.7 (1.0-3.0) | 1.9 (1.0-3.4) | 50 | 24 | 24 | 1.3 (0.8-2.2) | |||||
| Extent of skin lesions | .005 | .034 | .002 | .023 | ||||||||||||
| Solitary | 22 | 43 (5-164) | 89 | 68 | 59 | 1 | 1 | 81 | 61 | 54 | 1 | 1 | ||||
| Regional | 27 | 23 (1-235) | 74 | 39 | 39 | 1.9 (0.8-4.9) | 1.7 (0.7-4.4) | 62 | 29 | 29 | 2.0 (0.9-4.5) | 1.7 (0.6-4.4) | ||||
| Generalized | 45 | 20 (2-100) | 46 | 23 | 3.6 (1.6-8.5) | 3.0 (1.2-7.2) | 44 | 20 | – | 3.5 (1.7-7.4) | 3.2 (1.3-7.7) | |||||
| Characteristic . | No. . | Median survival, mo . | DSS, % . | Univariate analysis DSS . | Multivariate analysis DSS . | OS, % . | Univariate analysis OS . | Multivariate analysis OS . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 y . | 5 y . | 10 y . | HR (95% CI) . | P . | HR (95% CI) . | P . | 2 y . | 5 y . | 10 y . | HR (95% CI) . | P . | HR (95% CI) . | P . | |||
| Sex | .418 | .980 | ||||||||||||||
| Male | 64 | 25 (1-235) | 65 | 38 | 38 | 1 | 59 | 31 | 21 | 1 | ||||||
| Female | 36 | 20 (2-160) | 56 | 38 | 32 | 1.3 (0.7-2.2) | 54 | 37 | 30 | 1 (0.6-1.6) | ||||||
| Age | .395 | .043 | .071 | |||||||||||||
| < 60 y | 34 | 42.5 (3-215) | 70 | 40 | 40 | 1 | 70 | 40 | 36 | 1 | 1 | |||||
| ≥ 60 y | 66 | 19 (1-235) | 57 | 38 | 33 | 1.3 (0.7-2.2) | 47 | 29 | 16 | 1.7 (1.0-2.9) | 1.9 (0.9-4.0) | |||||
| Time interval between MF and LCT | .089 | .322 | .246 | .475 | ||||||||||||
| ≤ 24 mo | 63 | 30 (2-215) | 71 | 44 | 39 | 1 | 1 | 66 | 36 | 25 | 1 | 1 | ||||
| > 24 mo | 37 | 17 (1-235) | 46 | 29 | 29 | 1.6 (0.9-2.7) | 1.4 (0.7-2.5) | 42 | 26 | 23 | 1.3 (0.8-2.2) | 1.3 (0.7-2.3) | ||||
| Clinical stage at LCT | .021 | .046 | .224 | .002 | ||||||||||||
| Skin disease (stage IB + stage IIB) | 75 | 26 (1-235) | 69 | 44 | 44 | 1 | 1 | 59 | 36 | 26 | 1 | 1 | ||||
| Extracutaneous disease (stage IV) | 25 | 20 (3-215) | 42 | 23 | 17 | 1.9 (1.1-3.3) | 1.9 (1.0-3.7) | 42 | 23 | 17 | 1.4 (0.8-2.3) | 3.2 (1.5-6.6) | ||||
| CD30 expression | .003 | .039 | .007 | .068 | ||||||||||||
| Positive | 47 | 38 (1-215) | 78 | 55 | 50 | 1 | 1 | 70 | 49 | 33 | 1 | 1 | ||||
| Negative | 53 | 20 (2-235) | 48 | 24 | 24 | 2.3 (1.3-4.1) | 2.0 (1.0-3.7) | 46 | 19 | 16 | 2.0 (1.2-3.2) | 1.8 (1.0-3.3) | ||||
| Folliculotropic MF | .060 | .048 | .318 | |||||||||||||
| Absent | 69 | 25 (1-235) | 67 | 45 | 42 | 1 | 1 | 57 | 37 | 25 | 1 | |||||
| Present | 31 | 22 (2-134) | 52 | 25 | 25 | 1.7 (1.0-3.0) | 1.9 (1.0-3.4) | 50 | 24 | 24 | 1.3 (0.8-2.2) | |||||
| Extent of skin lesions | .005 | .034 | .002 | .023 | ||||||||||||
| Solitary | 22 | 43 (5-164) | 89 | 68 | 59 | 1 | 1 | 81 | 61 | 54 | 1 | 1 | ||||
| Regional | 27 | 23 (1-235) | 74 | 39 | 39 | 1.9 (0.8-4.9) | 1.7 (0.7-4.4) | 62 | 29 | 29 | 2.0 (0.9-4.5) | 1.7 (0.6-4.4) | ||||
| Generalized | 45 | 20 (2-100) | 46 | 23 | 3.6 (1.6-8.5) | 3.0 (1.2-7.2) | 44 | 20 | – | 3.5 (1.7-7.4) | 3.2 (1.3-7.7) | |||||
MF indicates mycosis fungoides; LCT, large-cell transformation; DSS, disease specific survival; OS, overall survival; HR, hazard ratio; and CI, confidence interval.
Missing data: extent of skin lesions: 6.